APA-Zitierstil (7. Ausg.)

Becker, J. C., Bröcker, E., Schadendorf, D., & Ugurel, S. (2016). Imatinib in melanoma: A selective treatment option based on KIT mutation status? Journal of clinical oncology, 25(7), . https://doi.org/10.1200/JCO.2006.08.9664

Chicago-Zitierstil (17. Ausg.)

Becker, Jürgen C., Eva-Bettina Bröcker, Dirk Schadendorf, und Selma Ugurel. "Imatinib in Melanoma: A Selective Treatment Option Based on KIT Mutation Status?" Journal of Clinical Oncology 25, no. 7 (2016). https://doi.org/10.1200/JCO.2006.08.9664.

MLA-Zitierstil (9. Ausg.)

Becker, Jürgen C., et al. "Imatinib in Melanoma: A Selective Treatment Option Based on KIT Mutation Status?" Journal of Clinical Oncology, vol. 25, no. 7, 2016, https://doi.org/10.1200/JCO.2006.08.9664.